Hypertension Journal

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2017 ) > List of Articles


Clinical and Laboratory Assessment of Patients with Suspected Primary Aldosteronism

Richard J Auchus

Citation Information : Auchus RJ. Clinical and Laboratory Assessment of Patients with Suspected Primary Aldosteronism. Hypertens J 2017; 3 (3):131-138.

DOI: 10.5005/jp-journals-10043-0084

License: CC BY 3.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2017; The Author(s).


How to cite this article

Auchus RJ. Clinical and Laboratory Assessment of Patients with Suspected Primary Aldosteronism. Hypertens J 2017;3(3):131-138.

  1. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986 Feb;118(2):819-823.
  2. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab 2010 Oct;95(10):4756-4761.
  3. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017 Nov:pii:65.
  4. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016 May;101(5):1889-1916.
  5. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014 Apr;37(4):253-390.
  6. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005 Apr;45(8):1243-1248.
  7. Reference values for aldosterone-renin ratios in normotensive individuals and effect of changes in dietary sodium consumption. Clin Chem 2011 Nov;57(11):1607-1611.
  8. A renaissance in primary aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management. Clin Chem 2015 Aug;61(8):1022-1027.
  9. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med 2017 Nov;167(9):630-641.
  10. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001 Sep;76(9):877-882.
  11. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol (Oxf) 2017 Dec;87(6):665-672.
  12. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2017 Apr;2(8):93136.
  13. Benign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids. Endocrinol Diabetes Metab Case Rep 2013 Sep;2013:130042.
  14. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014 Aug;99(8):2712-2719.
  15. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014 Jan;63(1):151-160.
  16. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009 Jul;94(7):2437-2445.
  17. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017 Sep;5(9):689-699.
  18. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009 Mar;94(3):869-875.
  19. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab 2014 May;99(5):1593-1598.
  20. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012 Nov;97(11):3965-3973.
  21. Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism. Surgery 2018 Jan;163(1):183-190.
  22. A chimeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992 Jan;355(6357):262-265.
  23. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992 May;116(10):813-820.
  24. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011 Feb;331(6018):768-772.
  25. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 2012 Aug;97(8):E1567-E1572.
  26. A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008 Aug;93(8):3117-3123.
  27. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013 Apr;45(4):440-444, 444e-444e2.
  28. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013 Sep;45(9):1055-1060.
  29. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013 Sep;45(9):1050-1054.
  30. CACNA1H mutations are associated with different forms of primary aldosteronism. EBioMedicine 2016 Nov;13:225-236.
  31. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 2015 Apr;4:e06315.
  32. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci U S A 2015 Aug;112(33):E4591-E4599.
  33. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 Apr;49(4):839-845.
  34. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015 Nov;386(10008):2059-2068.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.